单侧贝伐单抗治疗早产儿不对称视网膜病变后的结果。

IF 1.2 4区医学 Q3 OPHTHALMOLOGY

Journal of Aapos Pub Date : 2024-12-27 DOI:10.1016/j.jaapos.2024.104091

Daniel G Nelson, G Baker Hubbard, Amy K Hutchinson

引用次数: 0

摘要

在这项用单侧玻璃体内贝伐单抗（IVB）治疗的早产儿不对称视网膜病变（ROP）病例的回顾性研究中，一半的治疗患者不需要进一步的IVB，而另一半在初始治疗后平均12天需要连续的IVB。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Outcomes after unilateral bevacizumab treatment for infants with asymmetric retinopathy of prematurity.

In this retrospective study of asymmetric retinopathy of prematurity (ROP) cases treated with unilateral intravitreal bevacizumab (IVB), half of the treated patients did not require further IVB, whereas the other half required sequential IVB at a mean of 12 days after initial treatment.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Aapos 医学-小儿科

CiteScore

2.40

自引率

12.50%

发文量

159

审稿时长

55 days

期刊介绍： Journal of AAPOS presents expert information on children''s eye diseases and on strabismus as it affects all age groups. Major articles by leading experts in the field cover clinical and investigative studies, treatments, case reports, surgical techniques, descriptions of instrumentation, current concept reviews, and new diagnostic techniques. The Journal is the official publication of the American Association for Pediatric Ophthalmology and Strabismus.